Exchange: NASDAQ·Updated 07:30 PM EST
About SUPN
Supernus, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of treatments for patients living with central nervous system (CNS) diseases. Its portfolio includes treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company was founded in 2005 and is headquartered in Rockville, MD.